SBIR Phase I: MIcrobial Modulation of Gastrointestinal Digestive Efficiency and Inflammation

这个小企业创新研究（SBIR）一期项目旨在为公众消费提供一种新的益生菌产品，以解决日益严重的美国和全球肥胖问题以及相关的健康问题，如糖尿病和心脏病。根据疾病和预防中心的数据，美国60% -65%的成年人超重或肥胖。虽然生活方式的改变（饮食调整和增加体力活动）改善了这种情况，但复发并增加体重是有充分记录的。目前的治疗方法是有限的，包括手术和有充分记录的健康风险的药物。该产品被设计为在胃肠道内工作，减少宿主可用的能量量，并为消费者提供一种停止体重增加和降低复发风险的手段，并可能积极调节导致健康状况下降和导致医疗费用增加的潜在风险因素。这项研究的更广泛/商业影响将是降低肥胖的高发率。美国不断上涨的医疗费用已经有了充分的记录。其中大部分费用与肥胖增加有关，肥胖是糖尿病和心脏病等疾病发展的潜在因素，通常与腹围增加/炎症过程有关。据世界卫生组织称，世界人口的四分之三依靠某种形式的非医药产品来获得保健，这为未来的商业化提供了一个世界范围的销售机会。

This Small Business Innovation Research (SBIR) Phase I project is designed to provide a new probiotic product for public consumption that will address the rising US and global obesity issue and related concurrent increase in health problems such as diabetes and heart disease. According to the Centers for Disease and Prevention, 60-65% of the adult population in the US is overweight or obese. While implementation of lifestyle change (dietary modification and increased physical activity) improves this condition, relapse with additional weight gain is well documented. Current treatments are limited and include surgery and pharmacological agents with well documented health risks. This product is designed to work within the gastrointestinal tract, decreasing the amount of energy available to the host, and providing a means to the consumer to halt weight gain and decrease the risk of relapse, with possible positive modulation of underlying risk factors which contribute to declining health and contribute to increased health care costs. The broader/commercial impacts of this research will be to reduce the high incidence of obesity. The rising cost of health care in the US has been well documented. Much of this cost is associated with increasing obesity, an underlying factor in the development of diseases such as diabetes and heart disease, commonly associated with an increase in abdominal circumference/inflammatory processes. According to the World Health Organization, three-fourths of the world population depends upon some form of non-pharmaceutical product for health care, providing a world-wide marketing opportunity for future commercialization.